Oncology Ventures

Founder and Managing Partner Ben Freeberg leads investment decisions, drawing on his experience as an investor at Optum Ventures and Alpha Partners and as an early operator at value-based cancer care startup Thyme Care. The investment team includes Venture Associate Nandita Kotwani, who previously led digital product development at Memorial Sloan Kettering and advised community oncology practices at Flatiron Health. The firm’s advisory committee — which includes former UnitedHealth Group CMO Dr. Lee Newcomer and Threshold Ventures co-founder Emily Melton — provides deal-level and strategic input, though ultimate decision-making authority rests with Freeberg.

The firm sources through a network of cancer-center operating partners embedded in its advisory and limited-partner committees. LP Advisory Committee members include the COO of Texas Oncology, the President of Health Innovation and Policy at City of Hope, the General Manager of Navista at Cardinal Health, and the Chief Business Officer of Moffitt Cancer Center. These relationships give the firm early visibility into clinical pain points and the startups building solutions inside large health systems, creating a pipeline that is difficult for generalist investors to replicate.

Oncology Ventures operates as a venture capital firm, not a family office. It raises outside capital and deploys it into early-stage startups, evidenced by its structured LP Advisory Committee composed of senior executives from major cancer institutions. The firm does not publicly disclose fund vehicles or limited-partner names, but its governance model — with separate advisory and LP committees — aligns with institutional venture architecture rather than single-family-office discretion.

The available evidence points to direct investments in seed and early-stage startups. The firm’s public materials name specific portfolio companies — mPATH, Tono, Risa, Lumonus, OncoveryCare, Reimagine Care, Concr, SpotDoc, Gabbi, and Ignite — with no mention of fund-of-fund commitments or LP stakes in other venture funds. The investment team’s operator backgrounds and the firm’s advisory structure further suggest a direct-deal model built on clinical-network sourcing.

The firm targets seed and early-stage startups. Its website emphasizes "commercially-validated" companies, implying a focus on post-prototype, pre-growth businesses that have initial customer traction. The portfolio companies listed — including Tono with 15,000 patients under management and Risa with documented enterprise savings — evidence a preference for startups that can demonstrate real-world clinical or operational impact at the point of first institutional capital.

The firm does not invest in therapeutic drug development, medical devices, or biotechnology. Its entire focus is on healthcare data and technology companies that address cancer care's non-drug infrastructure: early-detection AI, patient-navigation platforms, data-interoperability tools, and care-coordination workflows. This focus is rooted in Freeberg’s thesis that the largest opportunity lies in deploying what oncology already knows — guideline-based care — rather than in novel drug discovery.

There is no evidence of a separate philanthropic foundation or charitable vehicle tied to Oncology Ventures. The firm’s public materials emphasize a venture-capital thesis grounded in the founder’s personal experience, but impact is framed through financial returns and clinical metrics — lives saved, hours freed, costs reduced — rather than through grant-making or donor-advised funds.